Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Lung Cancer

FDA Approves Imfinzi for Extensive-Stage Small Cell Lung Cancer

Diana Ernst, RPh

April 1, 2020

The approval was based on data from the CASPIAN study, an active-controlled, open-label trial that investigated the combination of durvalumab plus chemotherapy vs chemotherapy alone.

Breast Cancer

Neratinib Plus Capecitabine Approved for HER2-Positive Metastatic Breast Cancer

Diana Ernst, RPh

March 4, 2020

The FDA has approved neratinib (Puma Biotechnology), a kinase inhibitor, in combination with capecitabine, for the treatment of adult patients with advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received 2 or more prior anti-HER2 based regimens in the metastatic setting.

Side-Effect Management

Strontium89 Now Available for Relief of Metastatic Bone Pain

Diana Ernst, RPh

February 20, 2020

Strontium89 (Strontium Chloride Sr-89 injection), a radiopharmaceutical indicated for the relief of bone pain in patients with painful skeletal metastases, has been made available by Q BioMed.

General Oncology

FDA: Weight Loss Drug Possibly Linked to Cancer

Diana Ernst, RPh

January 22, 2020

Lorcaserin may potentially increase the risk of cancer, according to results from a clinical trial assessing the safety of the weight loss agent.

Genitourinary Cancer

Pembrolizumab Approved for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer

Diana Ernst, RPh

January 16, 2020

The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Breast Cancer

Ogivri, a Biosimilar to Herceptin, Now Available in the US

Diana Ernst, RPh

December 6, 2019

The approval of Ogivri was based on data demonstrating that the biosimilar product is highly similar to the reference product, Herceptin.

Leukemia

Biosimilar Truxima Now Available for Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia

Diana Ernst, RPh

November 12, 2019

Truxima (rituximab-abbs; Teva and Celltrion), a biosimilar to Rituxan (rituximab; Genentech) will be available in the US the week of November 11, 2019 for the treatment of adults with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

General Oncology

Cinvanti Single-Dose Regimen Approved for Patients Receiving Moderately Emetogenic Chemotherapy

Diana Ernst, RPh

October 29, 2019

Cinvanti injectable emulsion can be administered as a 2-minute intravenous injection or 30-minute intravenous infusion.

Next post in General Oncology